Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | RAD52 | P43351 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915244 | 0.89 | RAD52 (0.57) | HTR2CRAD52GFERMEN1KMT2A | |
| SCHEMBL6371126 | 0.86 | HTR2C (0.53) | HTR2CMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4026160 | 0.82 | ALDH1A1 (0.59) | HTR2CGFERMEN1KMT2ATSHR | |
| SCHEMBL21616841 | 0.78 | BACE1 (0.69) | BACE1LTA4HPTGS1PTGS2HRH3 | |
| SCHEMBL25692523 | 0.77 | MAPK8 (0.44) | GAASMN1; SMN2 | |
| SCHEMBL4521276 | 0.76 | ALDH1A1 (0.56) | MEN1KMT2AGAASMN1; SMN2KDM4E | |
| SCHEMBL30847362 | 0.76 | ALDH1A1 (0.56) | MEN1KMT2AGAASMN1; SMN2KDM4E | |
| SCHEMBL13946680 | 0.76 | LTA4H (0.55) | SMN1; SMN2TSHRBACE1LTA4HPTGS1 | |
| SCHEMBL5474831 | 0.76 | HTR2C (0.60) | HTR2CSMN1; SMN2LTA4H | |
| SCHEMBL4267515 | 0.76 | LTA4H (0.61) | HTR2CGAASMN1; SMN2LTA4HPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497265-B1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | GLAXO GROUP LIMITED | 2005-09-15 | — | — | US | disclosed |
| EP-1497265-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003089409-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | HTR7, HTR2C, HTR3C | HTR2C 2/4885RAD52 1469/4885GFER 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.